Medivir: The Collaboration with Daewoong Pharmaceutical for the Development of the Hepatitis B Compound, MIV-210 Has Been Discontinued
06-Sep-13 Stockholm, Sweden — Medivir AB (OMX:
MVIR) today announced that it has discontinued the development of its
hepatitis B compound MIV-210 based on a joint decision with Daewoong
Pharmaceutical Co. Ltd., (South Korea).
Under the terms of this
collaboration agreement Daewoong has been responsible for the R&D
work. MIV-210 has a demonstrably competitive antiviral activity but,
like other drugs of this class, does not completely eradicate HBV. The
commercial environment for HBV drugs, with the current standard of care
approaching generic status, requires a robust cure profile. To achieve
this cure profile would require combination with other drugs with
different and new mechanisms.
“In light of the characteristics
MIV-210 could offer for the treatment of Hepatitis B, we have together
with our partner Daewoong decided to abandon the development activities
with MIV-210”, said Maris Hartmanis, CEO, Medivir AB.
Labels: drugs in development, MIV-210